Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-6 Sublingual Tablets for Acute Perforator Artery Territory Infarction
ChiCTR2600129160Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cilostazol + dexborneol in brain infarction and ischemic stroke (5 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: mRS score (Phase 1 primary) and mRS score (Phase 2 primary). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cilostazol + dexborneol
03
Conditions
brain infarctionischemic stroke
Beyond the preview
Go deeper on ChiCTR2600129160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129160.